PureTech Health (LON:PRTC) Trading 14.2% Higher - Here's Why

Key Points

• PureTech Health plc shares rose by 14.2% during trading, reaching a peak of GBX 123.80 ($1.67) and closing at GBX 121.50 ($1.64), with trading volume increasing by over 1,000% compared to its average.
• The company has a market cap of £293.65 million and a notably high PE ratio of 714.71, along with strong liquidity ratios (quick ratio of 2.51 and current ratio of 3.68).
• Insider Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1 per share, indicating confidence from corporate insiders, who collectively own 13.13% of the company.

Shares of PureTech Health plc (LON:PRTC - ) were up 14.2% during trading on Friday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares were traded during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Trading Up 14.2%

The stock has a market cap of £293.65 million, a PE ratio of 714.71 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The company's 50-day moving average price is GBX 129.64 and its 200 day moving average price is GBX 129.95.

Insider Transactions at PureTech Health

In related news, insider Bharatt Chowrira acquired 167,739 shares of the firm's stock in a transaction on Thursday, July 3rd. The stock was bought at an average price of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is owned by corporate insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.